Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.95 |
| ▸ | ACVRL1 | P37023 | 12/20 | 0.95 |
| ▸ | RET | P07949 | 5/20 | 0.95 |
| ▸ | ROS1 | P08922 | 5/20 | 0.95 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.95 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.95 |
| ▸ | MET | P08581 | 2/20 | 0.64 |
| ▸ | IGF1R | P08069 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455390 | 1.00 | NTRK1 (0.95) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL441252 | 0.97 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL16437779 | 0.97 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL439697 | 0.90 | NTRK1 (0.87) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL453696 | 0.89 | NTRK1 (0.81) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL453697 | 0.89 | NTRK1 (0.81) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL469157 | 0.89 | NTRK1 (0.76) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL441107 | 0.88 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL439638 | 0.86 | NTRK1 (0.81) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL438554 | 0.86 | NTRK1 (0.81) | NTRK1ACVRL1RETROS1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170231930-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION | UNIVERSITE DE STRASBOURG (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9636377-B2 | Compositions and methods for the treatment of retinal degeneration | UNIVERSITE DE STRASBOURG (FR) | 2017-05-02 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150038432-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION | UNIVERSITE DE STRASBOURG (FR) | 2015-02-05 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2012037155-A2 | TYROSINE KINASE INHIBITORS | GTX, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | NTRK1 65/4885ACVRL1 592/4885RET 11/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | NTRK1 65/4885ACVRL1 592/4885RET 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.